Dipeptidyl-Peptidase IV Inhibitors
(Journal Article): Enhanced insulin secretion and improved glu-cose tolerance in mice lacking CD26.
Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, Ribel U, Watanabe T, Drucker DJ, Wagtmann N
IN:
Proc Natl Acad Sci U S A
2000; 97(12):6874-6879
Impact Factor(s) of Proc Natl Acad Sci U S A: 10.452 (2004), 10.272 (2003), 10.7 (2002), 10.896 (2001)
ABSTRACT:
A subset of prolyl oligopeptidases, including dipeptidyl-peptidase IV (DPP IV or CD26, EC ), specifically cleave off N-terminal dipeptides from substrates having proline or alanine...
Click HERE for details
(Journal Article): Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.
Reimer MK, Holst JJ, Ahren B
IN:
Eur J Endocrinol
2002; 146(5):717-727
Impact Factor(s) of Eur J Endocrinol: 3.14 (2004), 2.941 (2003), 2.133 (2001)
ABSTRACT:
OBJECTIVES: Inhibitors of the glucagon-like peptide-1 (GLP-1)-degrading enzyme, dipeptidyl peptidase IV (DPPIV), are being explored in the treatment of diabetes. We examined the lo...
Click HERE for details
(Journal Article): Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes.
Ahren B, Gomis R, Standl E, Mills D, Schweizer A
IN:
Diabetes Care
2004; 27(12):2874-2880
Impact Factor(s) of Diabetes Care: 7.071 (2004), 7.501 (2003), 5.477 (2002), 5.404 (2001)
ABSTRACT:
OBJECTIVE: To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with type 2 diabetes continuing metformin treatment. RE...
Click HERE for details
(Journal Article): What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Ahren B
IN:
Diabetologia
2005; 48(4):605-607
Impact Factor(s) of Diabetologia: 5.583 (2004), 5.689 (2003), 5.136 (2002), 6.299 (2001)
ABSTRACT:
n.a.
Click HERE for details
(Journal Article): What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?
Ahren B
IN:
Diabetologia
2005; 48(4):605-607
Impact Factor(s) of Diabetologia: 5.583 (2004), 5.689 (2003), 5.136 (2002), 6.299 (2001)
ABSTRACT:
n.a.
Click HERE for details
(Journal Article): The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1.
Nauck MA, El-Ouaghlidi A
IN:
Diabetologia
2005; 48(4):608-611
Impact Factor(s) of Diabetologia: 5.583 (2004), 5.689 (2003), 5.136 (2002), 6.299 (2001)
ABSTRACT:
n.a.
Click HERE for details
(Journal Article): Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors.
Holst JJ, Deacon CF
IN:
Diabetologia
2005; 48(4):612-615
Impact Factor(s) of Diabetologia: 5.583 (2004), 5.689 (2003), 5.136 (2002), 6.299 (2001)
ABSTRACT:
n.a.
Click HERE for details
(Journal Article): 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavail-able dipeptidyl peptidase IV inhibitor with antihyperglycemic properties.
Villhauer EB, Brinkman JA, Naderi GB, Burkey BF, Dunning BE, Prasad K, Mangold BL, Russell ME, Hughes TE
IN:
J Med Chem
2003; 46(13):2774-2789
Impact Factor(s) of J Med Chem: 5.076 (2004), 4.82 (2003), 4.566 (2002), 4.139 (2001)
ABSTRACT:
Dipeptidyl peptidase IV (DPP-IV) inhibition has the potential to become a valuable therapy for type 2 diabetes. The synthesis and structure-activity relationship of a new DPP-IV in...
Click HERE for details
(Journal Article): Dipeptidyl peptidase IV inhibition as an approach to the treatment and prevention of type 2 diabetes: a historical perspective.
Deacon CF, Holst JJ
IN:
Biochem Biophys Res Commun
2002; 294(1):1-4
Impact Factor(s) of Biochem Biophys Res Commun: 2.904 (2004), 2.836 (2003), 2.935 (2002), 2.946 (2001)
ABSTRACT:
n.a.
Click HERE for details
|
| Contribute
to this subject area!
|
|
|
